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OBJECTIVE— We assessed the lifetime risk of cardiovascular disease (CVD) among indi-
viduals with and without obesity and diabetes.
RESEARCH DESIGN AND METHODS— Participants were drawn from the original
and offspring cohorts of the Framingham Heart Study. Lifetime (30-year) risk of CVD was
assessed using a modified Kaplan-Meier approach adjusting for the competing risk of death,
beginning from age 50 years.
RESULTS— Over 30 years, the lifetime risk of CVD among women with diabetes was 54.8%
among normal-weight women and 78.8% among obese women. Among normal-weight men
with diabetes, the lifetime risk of CVD was 78.6%, whereas it was 86.9% among obese men.
CONCLUSIONS— The lifetime risk of CVD among individuals with diabetes is high, and
this relationship is further accentuated with increasing adiposity.
Diabetes Care 31:1582–1584, 2008
The prevalence of obesity among in-dividuals with diabetes continues torise (1). The lifetime risk of coronary
heart disease is 42% among men and 25%
among women (2) and is higher among
individuals with diabetes (3). However,
given the close relationship between obe-
sity and diabetes, it is important to evalu-
ate the joint impact of the presence of
obesity and diabetes on the lifetime risk of
cardiovascular disease (CVD). The pur-
pose of this study is to quantify the life-
time risk of CVD among individuals with
and without diabetes and obesity in the
Framingham Heart Study.
RESEARCH DESIGN AND
METHODS
Study design
Participants were drawn from the Fra-
mingham Heart Study. For details re-
garding the study sample, outcome
ascertainment, and diabetes diagnosis,
please see an online appendix avail-
able at http://dx.doi.org/10.2337/dc08-
0025.
All participants gave written in-
formed consent, and the study was ap-
proved by the institutional review board
of the Boston Medical Center.
Statistical analysis
All analyses were sex specific. Participants
who developed diabetes during follow-up
were allowed to contribute information to
both nondiabetic and diabetic categories
(transition in this direction was permit-
ted). Short- (10-year), medium- (20-year)
and long-term (30-year) risks of develop-
ing CVD were calculated for participants
with and without diabetes. The 30-year
risk estimate approximates the lifetime
risk in individuals aged 50 years or older.
The original cohort was further stratified
by BMI category; this was not done on the
offspring cohort due to fewer numbers of
events. The inclusion of the offspring co-
hort allows for the analysis of more con-
temporary data. For computing the 10-,
20-, and 30-year risks, we used the Prac-
tical Incidence Estimators macro ap-
proach developed by Beiser et al. (4)
based on a method proposed by Gaynor et
al. (5) as previously described (6). This
approach uses age as a time scale of anal-
ysis and adjusts for the competing risk of
death to avoid risk inflation introduced in
standard survival methods that do not
fully account for individuals who die dur-
ing follow-up (and, therefore, can no
longer develop the event of interest).
RESULTS— Table 1 presents the
number of individuals, BMI categories,
and CVD cases over the duration of fol-
low-up stratified by diabetes status. Over-
all, in the original cohort, the lifetime risk
of CVD was 38.7% in women and 55.4%
in men. In the offspring cohort, the life-
time risk of CVD in women was 27.2%
and 39.8% in men.
The 10-, 20-, and 30-year risk of
CVD by diabetes status
Over 30 years, the lifetime risk of devel-
oping CVD in the original cohort was
38.0% among women without diabetes,
whereas it was 67.1% among women with
diabetes (Table 1, middle panel). Among
men, the lifetime risk of CVD without di-
abetes was 54.8% and with diabetes
78.0%. Similar patterns were observed in
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the offspring cohort and with 10- or 20-
year risk data (Table 1, middle panel).
The 10-, 20-, and 30-year risk of
CVD by diabetes and BMI status
Over 30 years, the lifetime risk of CVD
among normal-weight women without
diabetes was 34.3% (Table 1, lower panel),
whereas it was 46.7% among obese
women without diabetes. Among women
with diabetes, the 30-year risk was 54.8%
among normal weight women and 78.8%
among obese women with diabetes. Sim-
ilar patterns were observed among men,
and the lifetime risk of CVD approached
90% among men with both obesity and
diabetes. Results are displayed graphi-
cally in the Online Supplemental Figure.
CONCLUSIONS— The lifetime (i.e.,
30-year) incidence of CVD adjusted for
mortality among participants with diabe-
tes was two-thirds to three-quarters in the
original cohort, and roughly one-half to
two-thirds in the offspring cohort. Life-
time risk varied according to BMI category,
with participants with obesity and diabetes
having the highest risk of developing CVD.
The lifetime risk of diabetes has been
estimated at 32.8% for men and 38.5%
for women (7). The lifetime risk of diabe-
tes increases in proportion to BMI, rang-
ing from 7.6% among underweight
individuals to as high as 74.4% among
individuals with stage 2 obesity (8). Sim-
ilarly, our findings demonstrate that the
lifetime risk of CVD is higher among in-
dividuals with both obesity and diabetes,
with the lifetime risk of CVD approaching
nearly 80% in obese women and nearly
90% in obese men.
Given the recent increases in both the
Table 1—Characteristics of study participants aged 50–89 years and the 10-, 20-, and 30-year risk of CVD by diabetes status†
Nondiabetic Diabetic Nondiabetic Diabetic
Women Men
Baseline characteristics and
follow-up information
Original cohort
Normal weight 1225 (48.0) 73 (33.2) 694 (35.6) 35 (17.5)
Overweight 880 (34.5) 69 (31.4) 998 (51.3) 113 (56.5)
Obese 448 (17.6) 78 (35.5) 256 (13.1) 52 (26.0)
New CVD events 1424 159 1267 146
Person-years follow-up 63765 2778 39685 2248
Offspring
Normal weight 931 (49.6) 40 (19.8) 399 (24.5) 39 (15.2)
Overweight 593 (31.6) 63 (31.2) 858 (52.6) 121 (47.3)
Obese 353 (18.8) 99 (49.0) 373 (22.9) 96 (37.5)
New CVD events 244 52 387 102
Person-years follow-up 28229 2027 23408 2573
Lifetime risk CVD*
Original cohort
10-year 6.9 (5.8–7.9) 21.6 (9.5–33.6) 15.0 (13.3–16.8) 28.2 (15.4–41.1)
20-year 21.7 (20.1–23.4) 50.0 (39.2–60.9) 36.0 (33.8–38.2) 57.7 (47.7–67.7)
30-year 38.0 (36.1–39.9) 67.1 (58.3–76.0) 54.8 (52.5–57.0) 78.0 (71.5–84.4)
Offspring
10-year 3.9 (3.0–4.9) 15.9 (7.2–24.6) 8.7 (7.1–10.2) 13.3 (7.1–19.5)
20-year 11.0 (9.2–12.7) 29.3 (19.8–38.7) 23.7 (21.3–26.2) 43.8 (36.1–51.6)
30-year 26.0 (22.6–29.4) 48.6 (38.5–58.7) 37.8 (34.3–41.3) 61.6 (53.9–69.3)
Lifetime risk of CVD stratified by
BMI category*
10-year
Normal weight 6.2 (4.7–7.6) 9.4 (0.0–22.1) 11.9 (9.3–14.5) 33.2 (6.3–60.0)
Overweight 6.8 (5.0–8.6) 16.5 (0.0–34.1) 15.1 (12.7–17.5) 21.5 (5.9–37.0)
Obese 9.3 (6.3–12.3) 41.9 (14.2–69.6) 22.8 (17.0–28.5) 47.6 (12.1–83.2)
20-year
Normal weight 18.8 (16.6–21.1) 33.7 (16.2–51.2) 30.9 (27.4–34.4) 54.0 (30.1–77.9)
Overweight 21.6 (18.9–24.4) 52.2 (34.6–69.9) 37.3 (34.2–40.3) 57.9 (45.4–70.4)
Obese 30.0 (25.6–34.3) 65.6 (47.1–84.1) 44.4 (37.9–50.8) 65.4 (40.2–90.6)
30-year
Normal weight 34.3 (31.6–37.0) 54.8 (39.0–70.5) 49.2 (45.4–52.9) 78.6 (63.7–93.4)
Overweight 38.7 (35.5–41.9) 69.3 (55.9–82.7) 55.5 (52.4–58.6) 74.0 (64.8–83.3)
Obese 46.7 (42.1–51.4) 78.8 (66.4–91.2) 66.8 (60.7–73.0) 86.9 (75.8–97.9)
Data are n, n (%), and odds ratio (95% CI). *Expressed as percent developing CVD, adjusted for the competing risk of death. For original cohort and offspring among
participants aged 50–89 years, 95% CIs are stratified by BMI category for the offspring cohort only. †In the original cohort, 0.08% of participants were lost to
follow-up, and in the offspring cohort, 0.5% of participants were lost to follow-up. In the original cohort, 10.3% of CVD events were fatal and in the offspring cohort,
5.4% were fatal.
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prevalence and incidence of diabetes,
projections for the burden of diabetes in
the U.S. by 2050 have increased to 48.3
million cases (9). We have already dem-
onstrated that the attributable risk of CVD
due to diabetes has increased (10); this
trend may continue to worsen if current
trajectories do not change.
Limitations of our study include the
selection of all white individuals, which
potentially limits generalizability. We did
not exclude individuals with type 1 dia-
betes; however, there are less than 10 in-
dividuals in our sample and, therefore,
this is unlikely to have affected the results.
Lastly, given the shorter follow-up time in
the offspring, we note that these are more
long-term than lifetime risk estimates.
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